<DOC>
	<DOCNO>NCT03010436</DOCNO>
	<brief_summary>Benralizumab type medicine call monoclonal antibody make research clinic ; work block specific protein body call interleukin-5 . The study medicine , benralizumab , yet approve doctor treat patient EGPA . It consider experimental drug study .</brief_summary>
	<brief_title>Benralizumab Treatment Eosinophilic Granulomatosis With Polyangiitis ( EGPA ) Study</brief_title>
	<detailed_description>This study open-label mean subject receive study medication . The medicine-benralizumab-will give subject addition medicine already take treat EGPA oral steroid ( e.g . prednisone ) medicine reduce activity immune system . Drugs sometimes use ( i.e. , standard care ) reduce activity immune system EGPA ( addition oral steroid ) include azathioprine , methotrexate , mycophenolate mofetil cyclophosphamide . Information stud drug get affect subject body health collect number test , procedure question . The study medicine , benralizumab , give subject one injection 30 mg skin every four week 12 week every 8 week 16 week total 5 treatment . During treatment phase study , study staff member call subject see , medication take able decrease steroid use . The study total 9 study visit 44 week time period . Everyone take part study continue receive his/her exist treatment EGPA ( although dose oral steroid may reduce study .</detailed_description>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<criteria>Informed Consent : Able give write informed consent prior participation study , include ability comply requirement restriction list consent form . Subjects must able read , comprehend , write level sufficient complete study related material . Gender Age : Male female subject &gt; 18 year old EGPA diagnosis : subject diagnose EGPA least 6 month base history presence : asthma plus eosinophilia ( &gt; 1.0x109/L and/or &gt; 10 % leucocyte ) plus least two follow additional feature EGPA 1 . A biopsy show histopathological evidence eosinophilic vasculitis , perivascular eosinophilic infiltration , eosinophilrich granulomatous inflammation ; 2 . Neuropathy , mono poly ( motor deficit nerve conduction abnormality ) ; 3 . Pulmonary infiltrates , nonfixed ; 4 . Sinonasal abnormality ; 5 . Cardiomyopathy ( establish echocardiography MRI ) ; 6 . Glomerulonephritis ( haematuria , red cell cast , proteinuria ) ; 7 . Alveolar haemorrhage ( bronchoalveolar lavage ) ; 8 . Palpable purpura ; 9 . ANCA positive ( MPO PR3 ) . Subjects receive cyclophosphamide include 4week washout prior visit 0 ( first injection ) . Subjects received methotrexate , azathioprine , mycophenolate mofetil induction regimen may include stable dose least 4 week prior visit 0 . Corticosteroid therapy : Subject must stable dose oral prednisolone prednisone ≥5 mg/day least 4 week prior visit 0 . Immunosuppressive therapy : If receive immunosuppressive therapy ( include methotrexate , azathioprine , mycophenolate mofetil , exclude restrict medication ) dosage must stable 4 week prior visit 0 study ( dose reduction safety reason permit ) . Female subject : Women childbearing potential ( WOCBP ) must use effective form birth control ( confirm Investigator ) . Effective form birth control include : true sexual abstinence , vasectomize sexual partner , Implanon , female sterilization tubal occlusion , effective IUD intrauterine device/IUS levonogestrel Intrauterine system , DepoProvera ( tm ) injection , oral contraceptive , Evra Patch ( tm ) Nuvaring ( tm ) . WOCBP must agree use effective method birth control , define , enrolment , throughout study duration within 16 week last dose IP , negative serum pregnancy test result Visit 0 . Women childbearing potential defined woman either permanently sterilize ( hysterectomy , bilateral oophorectomy , bilateral salpingectomy ) , postmenopausal . Women consider postmenopausal amenorrheic 12 month prior plan date visit 1 without alternative medical cause . The follow agespecific requirement apply : Women &lt; 50 year old would consider postmenopausal amenorrheic 12 month follow cessation exogenous hormonal treatment follicle stimulate hormone ( FSH ) level postmenopausal range . Women ≥50 year old would consider postmenopausal amenorrheic 12 month follow cessation exogenous hormonal treatment . All male subject sexually active must agree use acceptable method contraception ( condom without spermicide , vasectomy ) Visit 0 16 week last dose . Hypereosinophilic Syndrome Wegener 's Granulomatosis History cancer : Subjects basal cell carcinoma , localize squamous cell carcinoma skin , situ carcinoma cervix eligible provide subject remission curative therapy complete least 12 month prior date informed consent , assent applicable obtain . Subjects malignancy eligible provide subject remission curative therapy complete least 5 year prior date informed consent , assent applicable , obtain . A helminth parasitic infection diagnose within 24 week prior date informed consent obtain treat , fail respond standard care therapy . Pregnant nursing Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level ≥2.5 time upper limit normal ( ULN ) confirm screening period . If female childbearing potential , must negative pregnancy test must adhere acceptable method contraception ( &lt; 1 % failure rate ) study four month study . Receipt investigational non biologic within 30 day 5 halflives prior visit 0 , whichever longer . A history know immunodeficiency disorder include positive human immunodeficiency virus ( HIV ) test . Any medical illness precludes study involvement Positive hepatitis B surface antigen , hepatitis C virus antibody serology , positive medical history hepatitis B C. Subjects history hepatitis B vaccination without history hepatitis B allow enrol . Patients currently receive previously receive benralizumab type antiinterleukin therapy ( i.e . mepolizumab , reslizumab , lebrikizumab etc . ) within last 4 month 5 halflives whichever longer . History anaphylaxis biologic therapy vaccine . Receipt immunoglobulin blood product within 30 day prior date informed consent obtain . Taking cyclophosphamide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>